New members to the team

Philip Brainin, Analyst - Sound Bioventures

Philip Brainin, Analyst, MD, PhD, MBA

Today it was announced that Philip Brainin has joined the Sound Bioventures team.

Before joining Sound Bioventures in December 2022, Philip worked as an intern at Sunstone Life Science Ventures in Copenhagen, where he conducted due diligence on incoming deals and analyzed European cardiovascular biotech companies.

After earning his medical degree from Copenhagen University, Philip worked as a research fellow at Brigham and Women’s Hospital, Harvard Medical School to obtain his PhD degree. During his postdoctoral studies he established a biobank in the Brazilian Amazon Basin for which he was awarded the Lundbeck Foundation Talent Prize 2021 for dedicated young researchers. Subsequently, he worked with strategy support and business development for biotech start-ups and completed a Master of Business Administration at Copenhagen Business School, where he graduated with the highest GPA ever achieved in the program.

Philip will be based in the Copenhagen, Denmark, office

Anne Marie Simon, Office Manager

Today it was announced that Anne Marie Simon has joined the Sound Bioventures team.

Prior to working at Sound Bioventures, Anne Marie has worked in the Private Equity sector for 6 years where she was in charge of coordinating with all portfolio company boards, managing the calendar puzzle of CEO and Executive Advisers worldwide and organizing Harvard Seminars.

Anne Marie thrives in a proactive, supporting and organizing role and is motivated by a busy and rapidly changing environment. Reliable and responsible with a good sense of humor and a passion for people, management and leadership.

Anne Marie will be based in the Copenhagen, Denmark, office.

ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

-ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic – -First patient expected to be enrolled in Q2 2024- Valencia, Spain, February 28th, 2024 – ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the m ...

Subscribe

* indicates required